

Akari Therapeutics, Plc
22 Boston Wharf Road FL 7
Boston, MA 02210

October 25, 2023

Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549

**Re: Akari Therapeutics, Plc (the "Company")
Registration Statement on Form F-3 (the "Registration Statement")
Filed October 20, 2023
File No. 333-275119**

Dear Mr. Drory:

The Company hereby requests, pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, acceleration of effectiveness of the Registration Statement so that such Registration Statement will become effective as of 4:00 p.m. Eastern Time on October 26, 2023, or as soon thereafter as practicable.

[Signature Page Follows]

Very truly yours,

AKARI THERAPEUTICS, PLC

By: /s/ Rachelle Jacques

Name: Rachelle Jacques

Title: President and Chief Executive Officer
